Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION Savings from Off-Year Drug Re-Pricing Should Go Towards Medical Fees: JMA Chief
July 15, 2022
-
BUSINESS Pfizer Japan Files COVID-19 Vaccine for Ages 6 Months to 4 Years
July 15, 2022
-
REGULATORY Shionogi’s COVID-19 Pill Up for Expert Redeliberation on July 20
July 14, 2022
-
BUSINESS Shionogi’s Four-Day Workweek Not So Popular Yet, but Side Job Plan Gaining Traction
July 13, 2022
-
ORGANIZATION JPMA Think Tank Finds Surge in Japan-Unapproved Drugs in Areas with High Unmet Needs
July 12, 2022
-
REGULATORY After Abe’s Death, Pharma and Medical Circles Fret Shift to Austerity and Tougher Drug Pricing
July 11, 2022
-
BUSINESS As LOEs Loom, Can Mochida Roll Out Authorized Generics for Lexapro and Lialda?
July 8, 2022
-
REGULATORY All Eyes on Scope of Drugs Possibly Designated as Key Resources; Full Discussions after Upper House Poll
July 7, 2022
-
BUSINESS Lecanemab Accepted for US Review, Action Date Set for January: Eisai/Biogen
July 7, 2022
-
BUSINESS Astellas Looks to Beat Innovation Malaise through Organizational and HR Rejig
July 6, 2022
-
REGULATORY MHLW Preparing Inspection Manual after GMP Issues, Draft Due Out by March-End
July 5, 2022
-
BUSINESS Shionogi Starts Document Submission for COVID Pill in China
July 5, 2022
-
BUSINESS BMS Japan Launches New Head Office as It Looks to Spur Ideas through Casual Chats
July 5, 2022
-
BUSINESS Chugai Best-Paying Japan Pharma in FY2021, 25 Drug Makers Pay Average 8.33 Million Yen
July 4, 2022
-
BUSINESS 37 Pharma Execs Get 100 Million-Plus Yen in FY2021, Top 3 at Takeda: Securities Reports
July 1, 2022
-
REGULATORY Japan Begins TPOXX Clinical Research as It Braces for Monkeypox Outbreak
June 30, 2022
-
BUSINESS Wholesalers Bear Over 50 Billion Yen in Annual Costs Tied to Restricted Drug Supply: Crecon Estimate
June 29, 2022
-
BUSINESS Astellas/Sutro to Codevelop Next-Gen Immunostimulatory ADCs for Cold Tumors
June 29, 2022
-
BUSINESS Bimzelx as Driver, UCB Set to Derive Half of Global Sales from Immunology Biz
June 28, 2022
-
COMMENTARY Japan Should Accelerate Debate on Legalizing Cannabis-Derived Drugs for Refractory Epilepsies
June 27, 2022
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…